13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001782539
Total reported value
$131.5M
$131.5M
27 檔
49.9%
As reported in its official Q4 2025 Form 13F filing, Nan Fung Group Holdings Ltd's tracked investment portfolio stood at $131.5M with 27 total positions.
In Q4 2025, Nan Fung Group Holdings Ltd displayed an active expansion posture, initiating 4 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EVMN | Evommune Inc | Stock-Other | 22.08% | -12.76% | — | |
| 2 | MPLT | Maplight Therapeutics Inc | Stock-Other | 15.27% | +10.19% | — | |
| 3 | OCS | Oculis Holding AG | Stock-Other | 9.20% | -4.52% | — | |
| 4 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 6.19% | -0.13% | — | |
| 5 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 5.98% | +2.75% | — | |
| 6 | INCY | Incyte CORP | Stock-Healthcare | 5.22% | +0.46% | — | |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.71% | +0.63% | — | |
| 8 | ONC | Beone Medicines Ltd-adr | Stock-Other | 4.28% | -0.44% | — | |
| 9 | PCOR | Procore Technologies Inc | Stock-Tech | 3.47% | -0.86% | — | |
| 10 | HELP | Cybin Inc | Stock-Other | 3.37% | +3.14% | — | |
| 11 | ASND | Ascendis Pharma A/S | Stock-Other | 2.60% | -2.57% | EXIT | |
| 12 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 2.46% | +0.09% | — | |
| 13 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 2.18% | +0.15% | — | |
| 14 | LAB | Standard Biotools Inc | Stock-Other | 2.16% | — | — | |
| 15 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.15% | +0.57% | — | |
| 16 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.11% | +0.29% | — | |
| 17 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.37% | +1.20% | — | |
| 18 | ETHA | Ishares Ethereum Trust ETF | ETF-Other | 1.01% | -0.20% | — | |
| 19 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.91% | +0.13% | — | |
| 20 | IBIT | Ishares Bitcoin Trust ETF | ETF-Crypto | 0.71% | -0.11% | — | |
| 21 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.60% | -0.01% | — | |
| 22 | REPL | Replimune Group Inc | Stock-Other | 0.55% | — | — | |
| 23 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.45% | -0.24% | — | |
| 24 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.44% | — | — | |
| 25 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.29% | -0.09% | — | |
| 26 | RKLB | Rocket Lab CORP | Stock-Industrials | 0.24% | — | -87.05% | |
| 27 | BSLK | Bolt Projects Holdings Inc | Stock-Other | 0.03% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RANI | Rani Therapeutics Holdings-a | +0.2% | — | Unchanged |
| 2 | REPL | Replimune Group Inc | +0.1% | — | Unchanged |
| 3 | TRDA | Entrada Therapeutics Inc | 0% | — | Unchanged |
| 4 | RVMD | Revolution Medicines Inc | -0.1% | — | Unchanged |
| 5 | BSLK | Bolt Projects Holdings Inc | -0.2% | — | Unchanged |
| 6 | BOLT | Bolt Biotherapeutics Inc | -0.2% | — | Unchanged |
| 7 | HRMY | Harmony Biosciences Holdings | -0.3% | — | Unchanged |
| 8 | BCYC | Bicycle Therapeutics Plc-adr | -0.5% | — | Unchanged |
| 9 | KYMR | Kymera Therapeutics Inc | -0.8% | — | Unchanged |
| 10 | IBIT | Ishares Bitcoin Trust ETF | -1% | — | Unchanged |
| 11 | ACAD | Acadia Pharmaceuticals Inc | -1.2% | — | Unchanged |
| 12 | ARGX | Argenx Se - Adr | -1.4% | — | Unchanged |
| 13 | ETHA | Ishares Ethereum Trust ETF | -1.7% | — | Unchanged |
| 14 | ASND | Ascendis Pharma A/S | -1.9% | — | Unchanged |
| 15 | LAB | Standard Biotools Inc | -2% | — | Unchanged |
| 16 | LBRX | Lb Pharmaceuticals Inc | -2% | — | Unchanged |
| 17 | RKLB | Rocket Lab CORP | -2.1% | -87.05% | Trim |
| 18 | RXRX | Recursion Pharmaceuticals-a | -2.7% | — | Unchanged |
| 19 | MDGL | Madrigal Pharmaceuticals Inc | -2.9% | — | Unchanged |
| 20 | INCY | Incyte CORP | -3.2% | — | Unchanged |
| 21 | RYTM | Rhythm Pharmaceuticals Inc | -3.6% | — | Unchanged |
| 22 | ONC | Beone Medicines Ltd-adr | -4.7% | — | Unchanged |
| 23 | OCS | Oculis Holding AG | -6% | — | Unchanged |
| 24 | EVMN | Evommune Inc | — | NEW | New buy |
| 25 | MPLT | Maplight Therapeutics Inc | — | NEW | New buy |
| 26 | PCOR | Procore Technologies Inc | — | NEW | New buy |
| 27 | HELP | Cybin Inc | — | NEW | New buy |
| 28 | JOBY | Joby Aviation, Inc. | — | EXIT | Sold out |
According to official SEC Form 13F filings, Nan Fung Group Holdings Ltd reported a total U.S. public equity portfolio value of $131.5M across 27 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including EVMN, MPLT, OCS) accounted for 49.9% of total reported equity market value during Q4 2025.
Top New Position Initiated
EVMN
市值: $24.7M
Top Position Liquidated / Trimmed
JOBY
前期市值: $3.5M
During Q4 2025, Nan Fung Group Holdings Ltd's top holdings by market value included EVMN (22.1%)、MPLT (15.3%)、OCS (9.2%). The largest single position, EVMN, represented 22.1% of total portfolio value.
In Q4 2025, Nan Fung Group Holdings Ltd made 6 total portfolio adjustments, initiating 4 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.